Listed

Mesoblast Ltd

MESONasdaqCIK 1345099HealthcareFiscal year ends Jun 30

Revenue is not reported in this company’s XBRL financial statements.

Latest quarter: not reported

Last eight quarters

Full statements
Mesoblast Ltd, key figures for the last eight quarters
Line itemUnitShape over the periods
Revenue$
Gross margin%
Operating margin%
Net margin%
Diluted EPS$ per share
Free cash flow$

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$17.2mNet margin −593.9%
Diluted EPS−$0.08, FY2025
Free cash flow−$50.6m, FY2025
Mesoblast Ltd, key figures for the last five fiscal years
Line itemUnitFY20212021-06-30FY20222022-06-30FY20232023-06-30FY20242024-06-30FY20252025-06-30Shape over the periods
Revenue$m7.4Revenue, FY2021, twelve months to 2021-06-30$7.4m. XBRL concept ifrs-full:Revenue. 20-F filed 2023-08-31, accession 0001345099-23-000059.Report this figure10.2Revenue, FY2022, twelve months to 2022-06-30$10.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-08-29, accession 0001345099-24-000063.Report this figure7.5Revenue, FY2023, twelve months to 2023-06-30$7.5m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure5.9Revenue, FY2024, twelve months to 2024-06-30$5.9m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure17.2Revenue, FY2025, twelve months to 2025-06-30$17.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)
Net margin%(1329.2%)Net margin, FY2021, twelve months to 2021-06-30. net income / revenueNet income: −$98.8m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2023-08-31, accession 0001345099-23-000059.Revenue: $7.4m. XBRL concept ifrs-full:Revenue. 20-F filed 2023-08-31, accession 0001345099-23-000059.Report this figure(894.6%)Net margin, FY2022, twelve months to 2022-06-30. net income / revenueNet income: −$91.3m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2024-08-29, accession 0001345099-24-000063.Revenue: $10.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-08-29, accession 0001345099-24-000063.Report this figure(1091.7%)Net margin, FY2023, twelve months to 2023-06-30. net income / revenueNet income: −$81.9m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-08-29, accession 0001345099-25-000067.Revenue: $7.5m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure(1490.3%)Net margin, FY2024, twelve months to 2024-06-30. net income / revenueNet income: −$88.0m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-08-29, accession 0001345099-25-000067.Revenue: $5.9m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure(593.9%)Net margin, FY2025, twelve months to 2025-06-30. net income / revenueNet income: −$102.1m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-08-29, accession 0001345099-25-000067.Revenue: $17.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure
Diluted EPS$ per share(0.16)Diluted EPS, FY2021, twelve months to 2021-06-30−$0.16 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2023-08-31, accession 0001345099-23-000059.Report this figure(0.13)Diluted EPS, FY2022, twelve months to 2022-06-30−$0.13 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-08-29, accession 0001345099-24-000063.Report this figure(0.11)Diluted EPS, FY2023, twelve months to 2023-06-30−$0.11 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure(0.09)Diluted EPS, FY2024, twelve months to 2024-06-30−$0.09 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure(0.08)Diluted EPS, FY2025, twelve months to 2025-06-30−$0.08 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(63.5)Free cash flow, FY2023, twelve months to 2023-06-30. operating cash flow − capital expenditureOperating cash flow: −$63.3m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-08-29, accession 0001345099-25-000067.Capital expenditure: $264.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure(48.7)Free cash flow, FY2024, twelve months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: −$48.5m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-08-29, accession 0001345099-25-000067.Capital expenditure: $271.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure(50.6)Free cash flow, FY2025, twelve months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$50.0m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-08-29, accession 0001345099-25-000067.Capital expenditure: $680.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-08-29, accession 0001345099-25-000067.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Mesoblast Ltd
FundQuarter endedReported valueSharesPut or callChange on the quarter before
JANE STREET GROUP, LLC2026-06-30$16.1m1,189,800CallAdded+451,400
CITADEL ADVISORS LLC2026-06-30$9.9m734,700CallAdded+316,400
MORGAN STANLEY2026-06-30$9.7m718,608Added+204,177
BlackRock, Inc.2026-06-30$9.0m664,280Added+33,425
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$6.2m457,744Added+71,272
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$5.4m398,000CallAdded+170,600
GOLDMAN SACHS GROUP INC2026-06-30$5.4m395,612Reduced−1,603
BNP PARIBAS ASSET MANAGEMENT Holding S.A.2026-06-30$3.5m259,700New+259,700
UBS Group AG2026-06-30$2.7m200,053Added+67,480
Arax Advisory Partners2026-06-30$2.3m168,022Added+143,597

Recent filings

All 567 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Mesoblast Ltd, recent filings
FiledFormWhat it isAccession number
2026-10-2906:57 ET6-KReport of a foreign private issuerPeriod 2026-10-290001345099-26-000093
2026-10-1621:29 ET6-KReport of a foreign private issuerPeriod 2026-10-160001345099-26-000091
2026-10-1507:37 ET6-KReport of a foreign private issuerPeriod 2026-10-140001345099-26-000089
2026-10-1306:27 ET6-KReport of a foreign private issuerPeriod 2026-10-130001345099-26-000087
2026-09-2421:14 ET6-KReport of a foreign private issuerPeriod 2026-09-240001345099-26-000085
2026-08-2707:09 ET6-KReport of a foreign private issuerPeriod 2026-08-270001345099-26-000083
2026-08-2706:08 ET20-FAnnual report of a foreign private issuerPeriod 2026-06-300001345099-26-000081
2026-08-2520:43 ET6-KReport of a foreign private issuerPeriod 2026-08-250001345099-26-000078
2026-08-2409:36 ET6-KReport of a foreign private issuerPeriod 2026-08-240001345099-26-000076
2026-08-1817:34 ET6-KReport of a foreign private issuerPeriod 2026-08-170001345099-26-000074

Latest annual report

Form 20-F for the fiscal year ended Jun 30, 2026Filed Aug 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1345099
Tickers
MESO, MEOBF
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Jun 30
Incorporated in
C3
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:58 ET. Listed shows no prices and gives no investment advice.